Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease-Reference-Cited by-同舟云学术

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease

Published:2024-04 Issue:4 Volume:5 Page:100648
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Li Molly S.C.^ORCID,Lee Kirsty W.C.,Mok Kevin K.S.,Loong Herbert H.F.,Lam K.C.,Mok Florence S.T.,Chan Landon L.,Lau Y.M.,Chan K.P.,Ng Joyce T.Y.,Wong Wesley K.Y.,Lam Benjamin H.W.,Chen Allen C.C.,Lee Matthew M.P.,Chen Olivia H.,Mok Tony S.K.

Publisher

Elsevier BV

Reference14 articles.

1. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

2. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer;Ding;J Thorac Oncol,2017

3. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

4. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma;Kodama;Investig New Drugs,2021

5. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: a multicentre retrospective cohort study;Imaji;Eur J Cancer,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease: A Case Report;Internal Medicine;2024